OMADA CEO Duffy’s Structured Buying & Selling Signals Investor Confidence

Corporate News

Insider Activity at OMADA Health Inc. – What the Numbers Say

On August 7, 2026, OMADA Health Inc.’s chief executive officer, Sean P. Duffy, executed two purchases of the company’s common stock under a pre‑adopted 10‑B5‑1 trading plan. The transactions involved the acquisition of 5,545 shares at $8.28 and 3,083 shares at $9.18 per share. A subsequent purchase on August 10 added 12,942 shares at $24.81, reflecting a sharp price escalation from the $8–$9 range to approximately $25 per share. These acquisitions brought Duffy’s holdings to 424,803 shares, just shy of the 425‑k mark he maintained earlier in the month.

In addition to the buying activity, the filing discloses that Duffy sold 4,314 shares at $20.90 on June 26, and an equal quantity at $22.80 on August 7. He also sold 12,942 shares on August 10 at the $24.81 level. These sales, combined with the exercise and immediate liquidation of three stock‑option blocks (5,545; 3,083; 12,942 shares), indicate a disciplined, plan‑driven strategy rather than opportunistic market timing. The exercise of options under the 10‑B5‑1 plan converts them into cash at no cost to the company, followed by the sale of the shares, thereby locking in gains while managing downside exposure.

Implications for Investors

The dual nature of Duffy’s transactions—buying during a price surge and selling earlier at lower levels—signals a long‑term investment stance. His purchases at the $25 level coincide with the company’s 18.98 % weekly gain and its 52‑week high of $26.92, suggesting confidence that the current rally is sustainable. The sizeable option sales imply a willingness to realize gains and potentially hedge exposure. For shareholders, this behavior is reassuring: the CEO aligns his interests with the market, avoiding the perception of dumping shares at a discount.

OMADA Health’s market cap of $1.45 billion and a solid 19.51 % year‑to‑date gain underscore a company attracting both institutional and retail interest. Duffy’s recent large buy can be interpreted as a vote of confidence in the company’s growth trajectory. The 10‑B5‑1 plan also provides predictability, reducing the risk of insider panic sales that could trigger volatility. Investors should monitor subsequent plan trades; sustained buying is likely to support momentum, while large sell orders could temper enthusiasm.

Profile of Sean P. Duffy

Since the beginning of the year, Duffy has traded OMADA shares roughly every week, alternating between purchases of 8–12 k shares and sales of 3–12 k shares. His average buy price has ranged from $5.82 to $24.81, while his average sell price has been $19.00–$24.81. He has also exercised and sold options on three separate occasions, converting a total of 33,470 shares from options to cash. Over the past twelve months, Duffy has net‑owned just over 850,000 shares, a significant stake that aligns his incentives with shareholder value. His disciplined use of a 10‑B5‑1 plan suggests a long‑term horizon and a willingness to participate in upside while managing downside risk.

Bottom Line

The filing shows that CEO Duffy is both buying and selling in a structured, plan‑driven manner. His recent purchases at $25 reflect confidence in the stock’s trajectory, while his option sales demonstrate a willingness to lock in gains. For investors, this activity is a positive signal that aligns executive interests with shareholder returns and indicates that OMADA Health is positioned for continued growth, provided it can sustain the momentum that has driven recent price gains.